NeoGenomics/$NEO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NeoGenomics
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
- Ticker
- $NEO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Fort Myers, United States
- Website
- www.neogenomics.com
NeoGenomics Metrics
BasicAdvanced
$2.3B
-
-$0.25
-
-
Price and volume
Market cap
$2.3B
52-week high
$20.15
52-week low
$7.07
Average daily volume
2.4M
Financial strength
Current ratio
3.53
Quick ratio
3.036
Long term debt to equity
0.553
Total debt to equity
0.561
Interest coverage (TTM)
-10.66%
Profitability
EBITDA (TTM)
30.608
Gross margin (TTM)
44.77%
Net profit margin (TTM)
-4.10%
Operating margin (TTM)
-4.39%
Effective tax rate (TTM)
10.74%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
-1.57%
Return on equity (TTM)
-3.94%
Valuation
Price to revenue (TTM)
2.936
Price to book
2.89
Price to tangible book (TTM)
177.86
Price to free cash flow (TTM)
-80.927
Free cash flow yield (TTM)
-1.24%
Free cash flow per share (TTM)
-0.222
Growth
Revenue change (TTM)
11.08%
Earnings per share change (TTM)
-71.89%
3-year revenue growth (CAGR)
11.08%
10-year revenue growth (CAGR)
14.09%
3-year earnings per share growth (CAGR)
-31.26%
10-year earnings per share growth (CAGR)
0.28%
What the Analysts think about NeoGenomics
Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.
Analyst projections of the future price of NeoGenomics stock.
Bulls say / Bears say
NeoGenomics’ preliminary third-quarter revenue rose to about $209 million, with NGS revenue growth accelerating to roughly 28%. Management also said the stronger quarter should lift its full-year revenue guidance at the midpoint. (NeoGenomics)
The shift towards higher-value testing is starting to improve operating performance: second-quarter adjusted gross margin expanded by 260 basis points and adjusted EBITDA rose 36%. The company raised its 2026 revenue and adjusted EBITDA outlook. (NeoGenomics)
Medicare expanded coverage of RaDaR ST to monitor immunotherapy response in patients with late-stage solid tumours. This adds a third covered indication and could widen adoption of NeoGenomics’ MRD test. (NeoGenomics)
The non-clinical business remains a drag: second-quarter non-clinical revenue fell 15% year on year, with pharma services down 26%. Management expects non-clinical revenue to decline for 2026. (Simply Wall St, Seeking Alpha)
The return to quarterly profit has not yet translated into expected full-year GAAP profitability: NeoGenomics still forecasts a 2026 net loss of $34 million to $42 million. Second-quarter net income included an $11 million gain from extinguishing debt. (NeoGenomics)
Further RaDaR ST growth depends in part on broader reimbursement: two additional coverage submissions were still pending after Medicare added the immunotherapy-monitoring indication. Delayed or narrower decisions could limit the test’s commercial reach. (NeoGenomics)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
NeoGenomics Financial Performance
Revenues and expenses
NeoGenomics Earnings Performance
Company profitability
Upcoming events
No upcoming events
NeoGenomics News
AllArticlesVideos
Funds containing NeoGenomics
Fund name | Fund size | $NEO weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.21% |
iShares Ageing Population€AGED | $903M | 0.21% |
iShares Ageing Population£AGES | $953M | 0.21% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.